Fosun Pharma Receives WHO Prequalification for Its Second-generation Artesunate for Injection Argesun^®

The second-generation artesunate for injection Argesun^® independently developed by Fosun Pharma (600196.SH;02196.HK) was approved by WHO Prequalification(1)(WHO PQ) on 27 June 2023, which can enhance the accessibility of innovative antimalarial drugs and ultimately contribute to saving more lives.The first generation artesunate for injection (brand name Artesun^®), independently

WE Volunteer | Eco-Friendly Month

Henlius Forecasts Profit in 2023 H1 Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle

515 Fosun Family Day Sales Growth Beats Expectations, Gaining Popularity and Boosting Consumption

(30 June 2023) Shanghai’s two-month 4th Double Five Shopping Festival is drawing to an end, various themed activities continue to gain momentum. Inaddition to the Double Five Shopping Festival, the recent Dragon Boat Festival further unleashed consumption vitality. From 21 to 23 June, the offline consumer sales in Shanghai amounted to approximately RMB18.0 billion, and

Fosun International Included in S&P Global’s Sustainability Yearbook 2023 (China Edition) and Recognized as Industry Mover

Photo caption: Above are the S&P Global Sustainability Yearbook (China Edition)Emblems grantedby S&P Globalto Fosun International. Left is “Sustainability Yearbook Member (China Edition)”Emblem, right is “Industry Mover”Emblem.(28 June 2023) S&P Global held the “Creating Advantages, Seizing Sustainable Development Opportunities - S&P Global Sustainable1 Sustainabili